The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Randomized Trial of Intraarterial Infusion of Urokinase Within 6 Hours of Middle Cerebral Artery Stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan
Abstract
Background and Purpose— The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan was organized to determine the safety and clinical efficacy of intraarterial infusion of urokinase (UK) in patients with stroke within 6 hours of onset. Methods— Patients with ischemic stroke presenting within 6 hours of onset and displaying occlusions of the M1 or M2 portion of the middle cerebral artery on carotid angiography were randomized to the UK or control groups. Clinical outcome was assessed by the modified Rankin Scale, National Institutes of Health Stroke Scale, and Barthel Index. Results— The Independent Monitoring Committee recommended stopping the trial after approval of intravenous infusion of recombinant tissue plasminogen activator in Japan. A total of 114 patients underwent randomization, 57 patients in each group. Background characteristics were comparable between the 2 groups. The primary end point of favorable outcome (modified Rankin Scale 0 to 2) at 90 days was somewhat more frequent in the UK group than in the control group (49.1% and 38.6%, OR: 1.54, 95% CI: 0.73 to 3.23) but did not reach a significant level ( P =0.345). However, excellent functional outcome (modified Rankin Scale 0 to 1) at 90 days, a preplanned secondary end point, was more frequent in the UK group than in the control group (42.1% and 22.8%, P =0.045, OR: 2.46, 95% CI: 1.09 to 5.54). There were significantly more patients with National Institutes of Health Stroke Scale 0 or 1 at 90 days in the UK group than the control group ( P =0.017). The 90-day cumulative mortality was 5.3% in the UK group and 3.5% in the control group ( P =1.000), and intracerebral hemorrhage within 24 hours of treatment occurred in 9% and 2%, respectively ( P =0.206). Conclusions— The trial was aborted prematurely and the primary end point did not reach statistical significance. Nevertheless, the secondary analyses suggested that intraarterial fibrinolysis has the potential to increase the likelihood of excellent functional outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Cited by
Pathophysiology and treatment of stroke: present status and future perspectives
Kuriakose, D., & Xiao, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207609 · Cited by 1,350
Chalos, V., van der Ende, N. A. M., Lingsma, H. F., Mulder, M. J. H. L., Venema, E., Dijkland, S. A., Berkhemer, O. A., Yoo, A. J., Broderick, J. P., Palesch, Y. Y., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.026791 · Cited by 215
Treatment effects for which shift or binary analyses are advantageous in acute stroke trials
Saver, J. L., & Gornbein, J. (2009) · Neurology · doi:10.1212/01.wnl.0000341308.73506.b7 · Cited by 135
Mechanical thrombectomy for the treatment of acute ischemic stroke
Fields, J. D., Lindsay, K., Liu, K. C., Nesbit, G. M., & Lutsep, H. L. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.8 · Cited by 16
Metadata
- Authors
- Ogawa, A., Mori, E., Minematsu, K., Taki, W., Takahashi, A., Nemoto, S., Miyamoto, S., Sasaki, M., & Inoue, T.
- Venue
- Stroke
- Published
- 2007-10
- Volume
- 38
- Issue
- 10
- Pages
- 2633-2639
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2012982706
- Cited by
- 481
- References
- 1
- FWCI
- 22.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Trial of Intraarterial Infusion of Urokinase Within 6 Hours of Middle Cerebral Artery Stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan. https://app.cochat.ai/papers/10.1161/strokeaha.107.488551
- The paper
- Ogawa, A., Mori, E., Minematsu, K., Taki, W., Takahashi, A., Nemoto, S., Miyamoto, S., Sasaki, M., & Inoue, T. (2007). Randomized Trial of Intraarterial Infusion of Urokinase Within 6 Hours of Middle Cerebral Artery Stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan. Stroke. https://doi.org/10.1161/strokeaha.107.488551
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.